Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-17T07:50:07.965Z Has data issue: false hasContentIssue false
  • English
  • Français

The Pharmacology of Aminoglycosides: II. Distinctions Among the Agents

Published online by Cambridge University Press:  02 January 2015

Robert J. Geller  and
Sandra M. Norris
Robert J. Geller
Affiliation:
Department of Internal Medicine, University of Virginia Hospital, Charlottesville, Virginia
Sandra M. Norris
Affiliation:
Department of Internal Medicine, University of Virginia Hospital, Charlottesville, Virginia
Get access Rights & Permissions [Opens in a new window]

Extract

The first paper in this series dealt with the similarities among the aminocyclitol agents. In the following discussion, we will emphasize the differences among the commercially available aminoglycosides, highlighting the pharmacokinetic and toxicologic data affecting their rational use.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 5 , Issue 6 , June 1984 , pp. 298 - 302
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1984

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Norris, SM, Ravdin, JI. The pharmacology of aminoglycosides: I. Considered as a group. Infect Control 1984;5:188–191.CrossRefGoogle ScholarPubMed
2.Schentag, JJ, Jusko, WJ, Plaut, ME, et al: Tissue persistence of gentamicin in man. JAMA 1977;238:327–329.CrossRefGoogle ScholarPubMed
3.Schentag, JJ, Aminoglycoside tissue accumulation: A comparison between gentamicin and tobramycin in patients, in Weinstein, AJ (ed): Proceedings of A Symposium: Assessment of Aminoglycoside Toxicity. Indianapolis, Eli Lilly, 1978, pp 26–31.Google Scholar
4.Schentag, JJ, Cumbo, TJ, Jusko, WJ, et al: Gentamicin tissue accumulation and nephrotoxic reactions. JAMA 1978;240:2067–2069.CrossRefGoogle ScholarPubMed
5.Bennett, WM, Aronoff, GR, Morrison, G, et al: Drug prescribing in renal failure: Dosing guidelines for adults. American Journal of Kidney Diseases 1983;3:155–193.CrossRefGoogle ScholarPubMed
6.Angel, JE (publisher): Physician's Desk Reference 1984, ed 38. Oradell, NJ, Medical Economics, 1984.Google Scholar
7.Nelson, JD, Pocketbook of Pediatric Antimicrobial Therapy, ed 5. Dallas, Jodone Publishing, 1983.Google Scholar
8.Abramowicz, M (ed): Medical Letter Handbook of Antimicrobial Therapy, rev ed. New Rochelle, NY, Medical Letter Inc, 1982.Google Scholar
9.McHenry, MC, Therapeutic aspects of aminoglycoside antibiotics, in Barnes, WG, Hodges, GR (eds): The Aminoglycoside Antibiotics: A Guide to Therapy. Boca Raton, FL, CRC Press, 1984, pp 87–152.Google Scholar
10.Danish, M, Schultz, R, Jusko, WJ, Pharmacokinetics of gentamicin and kanamycin during hemodialysis. Antimicrob Agents Chemother 1974;6:841–847.CrossRefGoogle ScholarPubMed
11.Atkins, RC, Mion, C, Despaux, E, et al: Peritoneal transfer of kanamycin and its use in peritoneal dialysis. Kidney [n] 1973;3:391–396.Google ScholarPubMed
12.Szefler, SJ, Wynn, RJ, Clarke, DF, et al: Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr 1980;97:312–315.CrossRefGoogle ScholarPubMed
13.Taylor, WJ, Finn, AL (eds). Individualizing Drug Therapy: Practical Applications of Drug Monitoring. New York, Gross, Townsend, Frank, Inc, 1981, vol 1, pp 67–147.Google Scholar
14.Davies, JE, Resistance to aminoglycosides: Mechanism and frequency. Rev Infect Dis 1983;5(suppl 2):S261–S266.CrossRefGoogle Scholar
15.Moellering, RC Jr: Microbiological considerations in the use of tobramycin and related aminoglycosidic aminocyclitol antibiotics. Med J Aust 1977;2 (suppl):4–8.CrossRefGoogle ScholarPubMed
16.Guerrant, RL, Strausbaugh, LJ, Wenzel, RP, et al: Nosocomial bloodstream infections caused by gentamicin-resistant gram-negative bacilli. Am J Med 1977;62:894–901.CrossRefGoogle ScholarPubMed
17.Betts, RF, Valenti, WM, Chapman, SW, et al: Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984;100:219–222.CrossRefGoogle ScholarPubMed
18.Yurasek, MC, Wang, WL, Mostow, SR, Reduction in gentamicin resistance among gram-negative bacilli with the exclusive use of amikacin, abstracted. Clinical Research 1981;29:92A.Google Scholar
19.Moody, MM, dejongh, CA, Schimpff, SC, et al: Long-term amikacin use: Effects on aminoglycoside susceptibility patterns of gram-negative bacilli. JAMA 1982;248:1199–1202.CrossRefGoogle ScholarPubMed
20.Weinstein, MJ, Drube, CG, Moss, EL Jr, et al: Microbiologic studies related to bacterial resistance to gentamicin. J Infect Dis 1971; 124 (suppl):S11–S17.CrossRefGoogle ScholarPubMed
21.Dowding, JE, Mechanisms of gentamicin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1977;11:47–50.CrossRefGoogle ScholarPubMed
22.Santanam, P, Kayser, FH, Tobramycin adenylyltransferase: A new aminoglycoside-inactivating enzyme from Staphylococcus epidermide. J Infect Dis 1976;134 (suppl):S33–S39.CrossRefGoogle Scholar
23.Murray, BE, Karchmer, AW, Moellering, RC Jr, et al: Diphtheroid prosthetic valve endocarditis: Clinical presentation and therapy based on susceptibility to antimicrobial agents alone or in combination (Abstract #275), in Program and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, American Society for Microbiology, 1978.Google Scholar
24.Finland, M, Garner, C, Wilcox, C, et al: Susceptibility of recently isolated bacteria to amikacin in vitro: Comparisons with four other aminoglycoside antibiotics. J Infect Dis 1976;134 (suppl):S297–S307.CrossRefGoogle ScholarPubMed
25.Moellering, RC Jr: In vitro antimicrobial activity of the aminoglycoside antibiotics. Rev Infect Dis 1983;5 (suppl 2):S212–S231.CrossRefGoogle Scholar
26.Waitz, JA, Weinstein, MJ, Recent microbiological studies with gentamicin. J Infect Dis 1969;119:355–360.CrossRefGoogle ScholarPubMed
27.Thornsberry, C, Baker, CN, Kirven, LA, In vitro activity of antimicrobial agents on Legionnaires' disease bacterium. Antimicrob Agents Chemother 1978;13:78–80.CrossRefGoogle ScholarPubMed
28.Thornsberry, C, Kirven, LA, Antimicrobial susceptibility of Hemophilus influenzae. Antimicrob Agents Chemother 1974;6:620–624.CrossRefGoogle Scholar
29.Dalovisio, JR, Pankey, GR, In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin. J Infect Dis 1978;137:318–321.CrossRefGoogle Scholar
30.Finland, M, Garner, C, Wilcox, C, et al: Susceptibility of “Enterobacteria” to aminoglycoside antibiotics: Comparisons with tetracyclines, polymyxins, chloramphenicol, and spectinomycin. J Infect Dis 1976;134 (suppl):S57–S74.CrossRefGoogle ScholarPubMed
31.Sanders, CC, Sanders, WE Jr, Goering, RV, In vitro studies with Sch 21420 and Sch 22591: Activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci. Antimicrob Agents Chemother 1978;14:178–184.CrossRefGoogle ScholarPubMed
32.Kabins, SA, Nathan, C, Cohen, S, In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics. Antimicrob Agents Chemother 1976;10:139–145.CrossRefGoogle ScholarPubMed
33.Fu, KP, Neu, HC, In vitro study of netilmicin compared with other aminoglycosides. Antimicrob Agents Chemother 1976;10:526–534.CrossRefGoogle ScholarPubMed
34.Brummett, RE, Comparative ototoxicity of aminoglycoside antibiotics in a guinea pig model, in Weinstein, AJ (ed): Proceedings of a Symposium: Assessment of Aminoglycoside Toxicity. Indianapolis, Eli Lilly, 1978, pp 56–61.Google Scholar
35.Akiyoshi, M, Evaluation of ototoxicity of aminoglycoside antibiotics, in Weinstein, AJ (ed): Proceedings of a Symposium: Assessment of Aminoglycoside Toxicity. Indianapolis, Eli Lilly, 1978, pp 62–68.Google Scholar
36.Anniko, M, Aspects on the ototoxic potential of netilmicin. Acta Otolaryngol 1983;96:75–89.CrossRefGoogle ScholarPubMed
37.Smith, CR, Baughman, KL, Edwards, CQ, et al: Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349–353.CrossRefGoogle ScholarPubMed
38.Smith, CR, Lipsky, JJ, Laskin, OL, et al: Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302:1106–1109.CrossRefGoogle ScholarPubMed
39.Lerner, AM, Reyes, MP, Cone, LA, et al: Randomized controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983;1:1123–1127.CrossRefGoogle ScholarPubMed
40.Moore, RD, Smith, CR, Lipsky, JJ, et al: Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984;100:352–357.CrossRefGoogle ScholarPubMed
41.Sande, MA, Mandeli, GL, The aminoglycosides, in Gilman, AG, Goodman, LS, Gilman, A (eds): The Pharmacological Basis of Therapeutics, ed 6. New York, Macmillan, 1980, pp 1162–1180.Google Scholar
42.Schentag, JJ, Plaut, ME, Patterns of urinary beta-2 microglobulin excretion in patients treated by aminoglycosides. Kidney Int 1980;17:654–661.CrossRefGoogle ScholarPubMed
43.Kamme, C, Nephrotoxicity of gentamicin and tobramycin: A comparison in patients with serious infections, in Weinstein, AJ (ed): Proceedings of a Symposium: Assessment of Aminoglycoside Toxicity. Indianapolis, Eli Lilly, 1978, pp 43–52.Google Scholar